Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy. (ADEPT)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Nifedipine (Adalat GITS, BAY1040)
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Subjects are eligible to be included in the study only if they meet all of the following criteria:
- Aged 18 years or older, but less than 65 years;
- Either male or female
- BP is uncontrolled after at least 4 weeks of prior antihypertensive mono-therapy (the dosage of mono-therapy should be the starting dose of an angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), b-blocker (BB), calcium channel blocker (CCB), or diuretic) both in the beginning and at the end of the screening period (uncontrolled BP is defined as MSSBP ≥140 and <160mmHg and/or MSDBP ≥ 90 and <100mmHg, and in the presence of diabetes mellitus: MSSBP ≥130 and <160mmHg and/or MSDBP ≥80 and <100mmHg);
Exclusion Criteria:
- Subjects meeting any of the following criteria are to be excluded from the study:
- Known hypersensitivity to nifedipine or to any of the following excipients, hypromellose, polyethylene oxide, magnesium stearate, sodium chloride, iron oxide red (E172/C.I.77491), cellulose acetate, polyethylene glycol 3350, hydroxypropyl cellulose, propylene glycol, titanium dioxide (E171/C.I.77891)
- Evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma, hyperaldosteronism, etc.
Severe gastro-intestinal tract narrowing; gastric banding; kock pouch (ileostomy after proctocolectomy)
- Evidence of cardiovascular shock
- Pregnant, possibly pregnant, planning to become pregnant or lactating women Received combination (two or more than two drugs combination) therapy or higher dosage (a higher dosage is defined as a higher dosage than the standard recommended starting dosage presented in the label of each drug) mono-therapy in the beginning or at the ending of the screening period.
- History of cerebrovascular ischemic event (stroke or transient ischemic attack [TIA]) within 6 months
- History of intracerebral hemorrhage or subarachnoid hemorrhage
- History of hypertensive retinopathy
- Any history of heart failure, New York Heart Association (NYHA) classification III or IV Severe coronary heart disease as manifested by a history of myocardial infarction or unstable angina in the past 12 months or a history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Clinically significant cardiac valvular disease
- History of arrhythmia
- Type 1 diabetes mellitus (DM)
- Hyperkalemia history: a serum potassium level above the upper limit of normal in the laboratory range;
- Liver disease or aspartate transaminase (AST) or alanine transaminase (ALT) levels >3 x upper limit of normal (ULN)
- Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) of <30 mL/min, or on hemodialysis
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Arm 1
Arm Description
Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
Outcomes
Primary Outcome Measures
Percentage of subjects with a Mean Sitting Systolic Blood Pressure (<130mmHg for subjects with diabetes and <140mmHg for others) of Nifedipine GITs 60mg
Secondary Outcome Measures
Changes in the Mean Sitting SBP(MSSBP) and Mean Sitting DBP(MSDBP) from baseline at Week 8
Percentage of subjects with a Mean Sitting Systolic Blood Pressure Lower than 140mmHg and MSDBP less than 90 mmHg (130 and 80 for diabetis patients) of Nifedipine GITs 60mg
The percentage of subjects with a MSDBP lower than 90 (80 for diabetis)
The percentage of subjects achieving both a ≥10mmHg
Time to reach the MSSBP target (based on the BP measurements during office visits)
The MSSBP target means : 140 mmHg for others, 130 mmHg for diabetes
Changes in the 24-h, daytime (from 06:00 to 22:00), and nighttime (from 22:00 to 06:00) average SBP and DBP assessed by ABPM from baseline at Week 8
incidence of all treatment-emergent adverse events
incidence of drug-related treatment-emergent adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02413515
Brief Title
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
Acronym
ADEPT
Official Title
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapy: A Prospective, Open-label, Multicenter, Single-arm, 8-week Study.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
March 26, 2015 (Actual)
Primary Completion Date
August 8, 2016 (Actual)
Study Completion Date
August 8, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To evaluate antihypertensive efficacy and tolerability of Nifedipine GITS 60mg treated for 8 weeks in Chinese hypertensive subjects who failed to achieve BP control with the starting-dose antihypertensive monotherapy.
Detailed Description
Study design: it's a A prospective, open-label, multicenter, single-arm study. After a one- to two-week screening period, subjects receive Nifedipine GITS 60mg for 8 weeks.
The primary objective is to evaluate the antihypertensive efficacy of 8-week Nifedipine GITS 60mg treatment in Chinese hypertensive subjects who failed to achieve BP control with the starting-dose antihypertensive mono-therapy.
The secondary objective is to evaluate the tolerability of Nifedipine GITS 60mg.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
278 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Description
Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Nifedipine (Adalat GITS, BAY1040)
Intervention Description
Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
Primary Outcome Measure Information:
Title
Percentage of subjects with a Mean Sitting Systolic Blood Pressure (<130mmHg for subjects with diabetes and <140mmHg for others) of Nifedipine GITs 60mg
Time Frame
At week 8
Secondary Outcome Measure Information:
Title
Changes in the Mean Sitting SBP(MSSBP) and Mean Sitting DBP(MSDBP) from baseline at Week 8
Time Frame
baseline and week 8
Title
Percentage of subjects with a Mean Sitting Systolic Blood Pressure Lower than 140mmHg and MSDBP less than 90 mmHg (130 and 80 for diabetis patients) of Nifedipine GITs 60mg
Time Frame
At week 2 and week 4
Title
The percentage of subjects with a MSDBP lower than 90 (80 for diabetis)
Time Frame
At week 2 and week 4
Title
The percentage of subjects achieving both a ≥10mmHg
Time Frame
At week 8
Title
Time to reach the MSSBP target (based on the BP measurements during office visits)
Description
The MSSBP target means : 140 mmHg for others, 130 mmHg for diabetes
Time Frame
up to week 8
Title
Changes in the 24-h, daytime (from 06:00 to 22:00), and nighttime (from 22:00 to 06:00) average SBP and DBP assessed by ABPM from baseline at Week 8
Time Frame
baseline and week 8
Title
incidence of all treatment-emergent adverse events
Time Frame
At week 8
Title
incidence of drug-related treatment-emergent adverse events
Time Frame
at week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects are eligible to be included in the study only if they meet all of the following criteria:
Aged 18 years or older, but less than 65 years;
Either male or female
BP is uncontrolled after at least 4 weeks of prior antihypertensive mono-therapy (the dosage of mono-therapy should be the starting dose of an angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), b-blocker (BB), calcium channel blocker (CCB), or diuretic) both in the beginning and at the end of the screening period (uncontrolled BP is defined as MSSBP ≥140 and <160mmHg and/or MSDBP ≥ 90 and <100mmHg, and in the presence of diabetes mellitus: MSSBP ≥130 and <160mmHg and/or MSDBP ≥80 and <100mmHg);
Exclusion Criteria:
Subjects meeting any of the following criteria are to be excluded from the study:
Known hypersensitivity to nifedipine or to any of the following excipients, hypromellose, polyethylene oxide, magnesium stearate, sodium chloride, iron oxide red (E172/C.I.77491), cellulose acetate, polyethylene glycol 3350, hydroxypropyl cellulose, propylene glycol, titanium dioxide (E171/C.I.77891)
Evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma, hyperaldosteronism, etc.
Severe gastro-intestinal tract narrowing; gastric banding; kock pouch (ileostomy after proctocolectomy)
Evidence of cardiovascular shock
Pregnant, possibly pregnant, planning to become pregnant or lactating women Received combination (two or more than two drugs combination) therapy or higher dosage (a higher dosage is defined as a higher dosage than the standard recommended starting dosage presented in the label of each drug) mono-therapy in the beginning or at the ending of the screening period.
History of cerebrovascular ischemic event (stroke or transient ischemic attack [TIA]) within 6 months
History of intracerebral hemorrhage or subarachnoid hemorrhage
History of hypertensive retinopathy
Any history of heart failure, New York Heart Association (NYHA) classification III or IV Severe coronary heart disease as manifested by a history of myocardial infarction or unstable angina in the past 12 months or a history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
Clinically significant cardiac valvular disease
History of arrhythmia
Type 1 diabetes mellitus (DM)
Hyperkalemia history: a serum potassium level above the upper limit of normal in the laboratory range;
Liver disease or aspartate transaminase (AST) or alanine transaminase (ALT) levels >3 x upper limit of normal (ULN)
Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) of <30 mL/min, or on hemodialysis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
City
Tangshan
State/Province
Hebei
ZIP/Postal Code
063000
Country
China
City
Wudan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410008
Country
China
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710061
Country
China
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310006
Country
China
City
Beijing
ZIP/Postal Code
100028
Country
China
City
Beijing
ZIP/Postal Code
100037
Country
China
City
Beijing
Country
China
City
Shandong
Country
China
City
Shanghai
ZIP/Postal Code
200025
Country
China
City
Tangshang
Country
China
City
Tianjin
ZIP/Postal Code
300052
Country
China
12. IPD Sharing Statement
Learn more about this trial
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
We'll reach out to this number within 24 hrs